MCL1 and acute myeloid leukemia: Since expression levels of Mcl1 are regulated by proteasome-dependent degradation [31], we considered the possibility that bortezomib-induced stabilization of Mcl-1 might interfere with induction of cell death during antimitotic therapy in AML.